Buscar
01/04/2024
Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression
Young, AH, Baune, BT, Cardoner, N, Frey, R, Ito, T, Kambarov, Y, Lacerda, A, Rive, B, von Holt, C, Oliveira-Maia, AJ. Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression. EUROPEAN PSYCHIATRY. 2024; 67DOI:10.1192/j.eurpsy.2024.749. PMID:. IF:6.700(Q1/1D).
01/04/2022
Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat
Querol-Vilaseca, M, Sirisi, S, Molina-Porcel, L, Molina, B, Pegueroles, J, Ferrer-Raventos, P, Nunez-Llaves, R, Dols-Icardo, O, Balasa, M, Iulita, MF, Blesa, R, Belbin, O, Clarimon, J, Fortea, J, Gelpi, E, Sanchez-Valle, R, Lleo, A. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2022; 48(3)DOI:10.1111/nan.12781. PMID:34825396. IF:5.000(Q1/2D).
01/03/2022
Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis
Hostettler, IC, Wilson, D, Fiebelkorn, CA, Aum, D, Ameriso, SF, Eberbach, F, Beitzke, M, Kleinig, T, Phan, T, Marchina, S, Schneckenburger, R, Carmona-Iragui, M, Charidimou, A, Mourand, I, Parreira, S, Ambler, G, Jager, HR, Singhal, S, Ly, J, Ma, H, Touze, E, Geraldes, R, Fonseca, AC, Melo, T, Labauge, P, Lefevre, PH, Viswanathan, A, Greenberg, SM, Fortea, J, Apoil, M, Boulanger, M, Viader, F, Kumar, S, Srikanth, V, Khurram, A, Fazekas, F, Bruno, V, Zipfel, GJ, Refai, D, Rabinstein, A, Graff-Radford, J, Werring, DJ. Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis. JOURNAL OF NEUROLOGY. 2022; 269(3)DOI:10.1007/s00415-021-10706-3. PMID:34272978. IF:6.000(Q1/2D).
27/01/2022
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid
Gobom, J, Parnetti, L, Rosa-Neto, P, Vyhnalek, M, Gauthier, S, Cataldi, S, Lerch, O, Laczo, J, Cechova, K, Clarin, M, Benet, AI, Pascoal, TA, Rahmouni, N, Vandijck, M, Huyck, E, Le Bastard, N, Stevenson, J, Chamoun, M, Alcolea, D, Lleo, A, Andreasson, U, Verbeek, MM, Bellomo, G, Rinaldi, R, Ashton, N, Zetterberg, H, Sheardova, K, Hort, J, Blennow, K. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2022; 60(2)DOI:10.1515/cclm-2021-0651. PMID:34773730. IF:6.800(Q1/2D).